Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: Unjustified reluctance to treat

European Journal of Haematology

Volumn 72, Issue 4, 2004, Pages 264-267

  Laszlo, Daniele ^a   Agazzi, Alberto ^a   Goldhirsch, Aron ^a   Cinieri, Saverio ^a   Bertolini, Francesco ^a   Rabascio, Cristina ^a   Pruneri, Giancarlo ^a   Calabrese, Liliana ^a   Cocquio, Angela ^a   Martinelli, Giovanni ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Acute leukaemia; Jehovah's Witnesses tailored therapy; Transfusions

Indexed keywords

AMSACRINE; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HEMOGLOBIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RETINOIC ACID; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; JEHOVAH'S WITNESS; LEUKEMIA; MALE; PATIENT ATTITUDE; PRIORITY JOURNAL; RELAPSE; RELIGIOUS GROUP; SEPSIS; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE MANAGEMENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FEMALE; HEMOGLOBINS; HEMORRHAGE; HUMANS; JEHOVAH'S WITNESSES; LEUKEMIA; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PATIENT ACCEPTANCE OF HEALTH CARE; REFUSAL TO TREAT; REMISSION INDUCTION; TRETINOIN; VINCRISTINE;

EID: 12144286045     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0902-4441.2003.00211.x     Document Type: Article

References (9)

1. CULLIS J, DUNCOMBE A, DUDLEY J, LUMLEY H, APPERLEY J, SMITH A. Acute leukaemia in Jehovah's Witnesses. Br J Haematol 1998;100:664-668.
2. KERRIDGE I, LOWE M, SELDON M, ENNO A, DEVERIDGE S. Clinical and ethical issues in the treatment of a Jehovah's Witness with acute myeloblastic leukaemia. Arch Intern Med 1997;157:1753-1757.
3. GOMEZ-ALMAGUER D, RUIZ-ARGUELLES G, LOZANO DE LA VEGA A, GARCIA-GUAJARDO BM. Acute leukemia in Jehovah's Witnesses: difficulties in its management. Rev Invest Clin 1990;42:317-320.
4. YATES J, CLINDEWELL O, WIERNIK P et al. Cytosine arabinoside with daunomycin or adriamycin for therapy of acute myelocytic leukemia: a CALGB sudy. Blood 1982;60, 454-463.
5. GOLDBERG S, CHAN C, DAWKINS F, MEHLMAN T, SCHECHTER G. Should Jehovah's Witnesses be denied intensive chemotherapy for acute leukaemia? N Engl J Med 1990;322:777-778.
6. MAZZA P, PALAZZO G, AMURRI B, CERVELLERA M, RIZZO C, MAGGI A. Acute leucemia in Jehovah's Witnesses: a challange for hematologists. Haematologica 2000;85:1221-1222.
7. MAZZA P, PRUDENZANO A, AMURRI B, PALAZZO G, PISAPIA G, STANI L, PRICOLO G. Myeloablative therapy and bone marrow transplantation in Jehovah's Witnesses with malignancies: single center experience. Bone Marrow Transplant 2003;32:433-436.
8. TAKEUCHI S, UTSUNOMIYA A, MARINO T et al. Successful treatment for acute lymphoblastic leukaemia without blood transfusion in a Jehovah's Witness. Am J Hematol 1999;60:168-169.
9. MENDEZ A, SVARCH E, MARTINEZ E, HERNANDEZ P. Successful treatment of acute promyelocytic leukemia using all-trans retinoic acid and erythropoietin in a Jehovah's Witness boy. Ann Hematol 1998;76:43-44.